Skip to main content
. 2012 Feb 21;20(5):1056–1062. doi: 10.1038/mt.2012.27

Figure 2.

Figure 2

Recurrence-free intervals (RFIs) in melanoma patents following anti-CD20 therapy. So far, the median of RFI has not been reached. Patients #1 to #5 are still tumor-free, although anti-CD20 therapy has been terminated after 2 years. The median RFI following anti-CD20 therapy is 42+ months (mean: 27.4+). Patients #6 to #9 experienced disease recurrence at the time points given in the graph, patients #7 to #9 died from the disease.